(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/181215 A1

(51) International Patent Classification:
C07K 16/22 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:
PCT/EP2025/055309

(22) International Filing Date:
27 February 2025 (27.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24160771.2 01 March 2024 (01.03.2024) EP
63/723,664 22 November 2024 (22.11.2024) US

(71) Applicant: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE).

(72) Inventors: **BRUNNER, Andreas-David**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **DITTUS, Lars**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **GUPTA, Priyanka**; c/o VP, IP, Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). **LIZE, Muriel**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **MYZITHRAS, Maria Bonatsakis**; c/o VP, IP, Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). **RYBINA, Irina**; c/o VP, IP, Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). **SAUER, Julia**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **SKRONSKA-WASEK, Wioletta Anna**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **STAHL, Heiko Friedrich**; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(74) Agent: **LUTZE, Oliver** et al.; Boehringer Ingelheim International GmbH, Global Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: ANTIBODIES TO CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AND USES THEREOF

(57) Abstract: The present disclosure generally relates to anti-CTGF (connective tissue growth factor) antibodies or antigen-binding fragments thereof. Exemplary anti-CTGF antibodies disclosed herein address the need for treatments of conditions modulated by CTGF signaling. In some aspects, the anti-CTGF antibodies or antigen-binding fragments thereof are for diagnostic and/or therapeutic use, for example in a subject in need thereof, such as a human.

WO 2025/181215 A1